ImmunoGen, Inc. IMGN, a biotechnology company that develops
novel anticancer therapeutics using its antibody-drug conjugate (ADC)
technology, announced the results from Roche's TH3RESA Phase III trial
being presented today at the European Cancer Congress (ECC) in Amsterdam
(abstract #LBA15). The findings were accepted as late-breaking data and
also included in the Congress's official press program.
The TH3RESA study assessed Kadcyla (ado-trastuzumab emtansine) for the
treatment of advanced HER2-positive breast cancer that had progressed
despite prior treatment with at least two HER2-targeted medicines. At a
minimum, patients must have received Herceptin® (trastuzumab), Tykerb®
(lapatinib), and a taxane. The trial included approximately 600 patients
who were randomized, on a two-to-one basis, to receive either Kadcyla or
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in